Danggui Buxue decoction ameliorates blood deficiency syndrome by suppressing IL-6/JAK2/STAT3 signaling pathway: An integrated Chinmedomics and bioinformatics study - PubMed
3 hours ago
- #Metabolomics
- #STAT3 Signaling
- #Traditional Chinese Medicine
- Danggui Buxue Decoction (DBD) is effective in treating blood deficiency syndrome (BDS) but its mechanisms were unclear.
- The study used a benzene-induced BDS mouse model to analyze DBD's bioactive components via UPLC-Q/TOF-MS.
- DBD corrected nicotinate and nicotinamide metabolism and improved hematopoietic function in the BDS model.
- DBD reduced inflammatory cytokines (IL-6, IL-17, TGF-β) and suppressed the STAT3 signaling pathway (p-JAK2/JAK2, p-STAT3/STAT3).
- Eleven prototype components and three metabolites from DBD were identified, with astragaloside IV binding strongly to STAT3.
- Molecular dynamics simulations and CETSA confirmed astragaloside IV's binding stability to STAT3.
- DBD alleviates BDS by normalizing metabolic imbalance and inhibiting the IL-6/JAK2/STAT3 pathway.
- Astragaloside IV is a key bioactive compound in DBD with high affinity for STAT3.